Compare First Solar, Inc. (FSLR) vs Mesoblast Limited (MESO) Price & Performance

First Solar (FSLR) trades at $180.13, up 0.18% on the day, amid a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 32.47% net income margin and trades at a P/E of 11.03, below industry averages. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed. Analyst consensus is a Moderate Buy with a $267.59 price target, signaling significant upside potential despite recent sector-wide pressures and high put option activity noted in early October 2026.

The outlook for FSLR is mixed: strong earnings growth and attractive valuation support long-term upside, but near-term risks include solar sector volatility, rising borrowing costs, and patent litigation. Investors face a divergence between bullish fundamentals and bearish technicals, with the stock trading 33% below analyst targets. Key catalysts are Q3 2026 earnings and resolution of legal challenges, while headwinds include interest rate sensitivity and competitive pressures.

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.